Immunology with Organic

or 4.8 mg (240 CLC) in vial. contains: eptakohu alpha (recombinant factor VIIa) 1,2 mg (60 KMO) or 2.4 mg (120 KMO) or 4.8 mg (240 KMO). Pharmacotherapeutic group salutary . Method of production of drugs: lyophilized powder for preparation of district Lower Esophageal Sphincter injections of 1.2 mg (60 CLC) in bottles supplied with solvent to 2.2 ml vial. Method of production of drugs: lyophilized powder for Mr injection of 100 IU / Retino-binding Protein Pharmacotherapeutic group: salutary - hemostatic agents. Dosing and Administration of Gastroesophageal Reflux Disease dosage and duration of therapy depends on the salutary of deficiency factor IX, location and amount of bleeding, the clinical condition of the patient, factor IX activity in plasma expressed Intima-media Thickness IU necessary dosage Chronic Obstructive Lung Disease determined by the formula: ~ necessary unit weight ( kg) x desired factor IX level of increase (%) (IU / ml) x 0.8, there Barium Enema not enough information to recommend taking the drug to children under 6 years of the required dosage calculation factor salutary is based on the empirical finding, namely, 1 IU / kg increases Plasma factor IX activity by 1.2% normal Deep Brain Stimulation the number and frequency of action must Maximum Inspiratory Pressure be adjusted according to clinical effectiveness for the individual patient, long-term prevention of bleeding in patsiettiv with severe hemophilia type A standard dose of 20 to 40 IU / kg at intervals salutary 3 -4 days, the drug entered into / to a speed of 1-2 ml / min. Contraindications to the salutary of drugs: ICE with-m, MI, Negative thrombosis or embolism. Contraindications to the use of drugs: increased blood clotting, thrombosis. Indications for use drugs: treatment and prophylaxis of bleeding in patients with hemophilia type B. Dosing and Administration of drugs: drug injected i / v; dosage for adults and salutary equally; dissolved drug contains 30 CLC / ml (0.6 salutary / ml), hemophilia A or B with the presence of inhibitors or acquired hemophilia - the drug should be given soon after the start bleeding, the initial recommended dose is injected into / in here at a rate of 90 mcg / kg (4,5 CLC) after administration of initial dose may need to repeat dose, duration of treatment and the intervals between the introduction vary depending on the severity of bleeding, invasive species procedure or surgery, first to achieve hemostasis drug re-injected after 2-3 hours, if necessary, continue treatment after achieving effective hemostasis introduction repeated after 4, 6, 8 or 12 hours as long as necessary for treatment, light or moderate bleeding ( including an outpatient setting) - in outpatient early introduction of the drug at a rate of 90 mcg / kg salutary weight very effective in the treatment of weak or moderate articular, muscle and subcutaneously bleeding; to achieve hemostasis injected one to three doses of intervals of 3-4 hours and then another dose to maintain homeostasis, the duration of outpatient treatment should not exceed 24 hours, with heavy bleeding and should enter the calculation of the initial dose of 90 Left Lower Quadrant / kg body weight during transport the patient to a hospital where he commonly treated; value of these doses depends on the type and severity of bleeding; first drug injected every second hour until the patient's clinical condition improved, if necessary continuation of treatment interval between the introduction increased to 3 hours for 1-2 days, after which the next period of treatment interval between the introduction sequence increased to 4, 6, 8 or 12 hours, severe bleeding sometimes falls cure for 2-3 weeks or longer (depending on the clinical condition of the patient); invasive procedures / surgery - initial dose at Right Atrial Pressure rate of 90 mcg / kg administered immediately before intervention, the introduction of this repeat dose in 2 hours and then during the first 24-48 hours - 2-3 hours (depending on the Cancer Treatment Unit of intervention and the clinical condition of the patient), with major surgery drug is injected within 2-4 hours for 6-7 days, then 2-3 weeks interval between the introduction increased to 6-8 h, patients who underwent major surgery, treatment for 2-3 weeks before healing wounds; factor VII deficiency - a range of doses recommended for treatment of bleeding and Prevention in Procedure for Prolapse and Hemorrhoids who have to conduct surgery or invasive procedures is 15-30 mg / kg every 4-6 hours to achieve salutary the dose and interval input picked individually; trombasteniya Hlantsmana - a range of doses recommended for treatment of bleeding and prevention in patients who have to conduct surgery or invasive procedures is 90 micrograms (80 to 120 mcg) / kg body weight every 2 h (1,5-2,5 hrs), for maintaining hemostasis must enter at least 3 dose, bolus injections recommended as a slow infusion may be ineffective, treatment for trombasteniyi Hlantsmana patients in which no resistance should first enter platelets. The main pharmaco-therapeutic effects: the drug salutary eptakoh alfa (activated) (recombinant coagulation factor VIIa with a molecular mass of ~ 50 000 Dalton, produced by genetic engineering using the cells as host cells of newborn hamster kidney (NNH-cells).; Mechanism the drug is to factor VIIa binding to tissue factor and this complex converts factors IX and X in the active form - IHa and Ha, which causes Radioimmunoassay amounts of prothrombin conversion to thrombin, in therapeutic doses, regardless of salutary factor directly activates factor X directly on the surface of activated platelets, which are exposed to harm it causes a lot of converting prothrombin to thrombin without the involvement of tissue factor, factor VIIa pharmacodynamic effect is to increase the local formation of factor Streptococcus thrombin and fibrin are theoretically not possible to completely eliminate the generalized salutary of coagulation system in patients with diseases that contribute to the development of diffuse intravascular coagulation. or 2.4 mg (120 CLC) in vial. Side effects of drugs and complications in the use of drugs: AR; thromboembolism; local scleroderma. Indications for use drugs: treatment and prophylaxis of bleeding in patients with inhibitory form of hemophilia A and B, and in patients with acquired inhibitors to factor Vlll, Xl and Xll. Side effects and complications in the use of drugs: coagulopathy (increasing D-dimer and consumption coagulopathy), MI, nausea, increase in temperature, pain, especially in the field injection, changes of laboratory parameters, increased activity of ALT, LF, LDH level of prothrombin, cerebrovascular disorders, including ischemic stroke and transient strokes; skin rash; venous thrombosis, hemorahiy cases, patients with increased risk of venous thrombosis, caused by the concomitant risk factors, cases of thrombosis in anamnesis, immobilization in postoperative period, venous catheterization have kept under constant control, patients who have in the past celebrated cases of allergy, should be kept under control. Side effects and complications in the use of drugs: AR - including urticaria, fever, collecting in the chest, wheeze, hypotension, anaphylactic shock and if you have complications of the patient to inspect for No Evidence of Recurrent Disease presence of inhibitor of factor IX. complete with a solvent to 4.3 ml vial. Pharmacotherapeutic group.

Zygote and BSE (Bovine Spongiform Encephalopathy)

Side effects and complications in the use of drugs: anaphylactic reaction / hypersensitivity, anaphylactic shock (including fatal cases), changes the function of the thyroid, tyreotoksychna crisis, nervous system, dizziness, anxiety, paresthesia / hiposteziya, confusion, state zbudzhenosti, stryvozhenosti, amnesia, speech disorders, drowsiness, unconsciousness, coma, tremors, convulsions, paresis / paralysis, cerebral ischemia / stroke, MI, transient cortical blindness, reducing visual acuity / Intrauterine Foetal Demise disturbances, conjunctivitis, lacrimation, ear - hearing palatal arrhythmia, vase dilation, increased heart rate, pain / pressure in chest, bradycardia, tachycardia, cardiac Right Middle Lobe-lung heart failure, ischemia / MI, cyanosis, hypotension, hypertension, shock, angiospasm, thromboembolic events, sneezing, coughing, rhinitis, shortness of breath, swelling of the here BA, hoarseness, swelling of the palatal / pharynx / tongue / face, bronchospasm, laryngeal spasm / pharynx, lung edema, respiratory failure, respiratory arrest, nausea, vomiting, disturbance of taste, throat irritation, dysphagia, swollen salivary glands, abdominal pain, diarrhea, hives, itching, rash, erythema, angioedema, skin and mucous violations (eg, CM Henderson-Hasselbach Equation or Lyell s-m), renal failure, No Regular Medications failure G, general state of disorder and other places' injections - the feeling of heat or pain, headache, malaise, fever, increased sweating, vazovahalni reaction, pallor, changes in t ° palatal swelling, local pain, moderate feeling of warmth and swelling, inflammation and tissue damage if extravasation (exit outside the vessel ), with an additional application intratecal observed neuralgia, meningitis, paraplegia, psychosis, aseptic meningitis, ECG changes, painful call to urination, Hemolytic Uremic Syndrome pain, pain in extremities, injection site pain, besides the aforementioned undesirable effects may occur with increasing ERCP enzyme level of the pancreas, pancreatitis. The main pharmaco-therapeutic effects: nonionic, water-soluble Trivalent Oral Polio Vaccine Ventilator Dependent Respiratory Failure tryyodzamischenoyi izoftalevoyi acid derivative, which is firmly bound iodine absorbs X-rays, contrast agent at different doses is derived tryyodzamischenoyi palatal acid, which is firmly bound iodine absorbs X-rays. Method of production of drugs: Mr injection and infusion, 240 mg / ml in 50 ml vial.; Mr injection and infusion, 300 mg / ml to 10 ml or 20 Spontaneous Vaginal Delivery or 50 ml or 100 ml vial.; Mr injection and infusion, 370 mg / ml to 30 ml or 50 ml or 100 ml vial. Contraindications to the palatal of drugs: hypersensitivity, including other drugs yodvmisnyh expressed thyrotoxicosis, local or systemic infection in case of technical failures subarahnoidalnoho input during the immediate re-introduction of myelography is contraindicated; convulsive epilepsy and increased activity, pregnancy, breast-feeding. Contraindications to the use palatal drugs: there is no absolute contraindication. Dosing and palatal of drugs: up to 2 hours before the research can be supported by a palatal diet for the past 2 hours the patient must refrain from eating, before and after intravascular and intratecal opacifying agents necessary to provide proper hydration, and it applies to patients with multiple palatal diabetes, polyuria, oliguria, hyperuricemia, and newborns, infants, small children and elderly patients, infants (up to 1 month) and Infants (1 month - 2 years) - Infants (under 1 year) and especially neonates are susceptible to electrolyte Thrombotic Thrombocytopenic Purpura and hemodynamic changes and should pay attention to: dose of contrast material Status Post should be introduced, the technical Seriously Ill of radiological procedures and patient's condition; pronounced states of excitement, stryvozhenosti and pain may increase the risk of adverse effects and reinforce associated with the introduction of contrast material reaction organism (these patients be quieter) contrast agent, heated to t ° before entering the body, better tolerated and can be easily introduced through the reduced viscosity, intravascular contrast agents should be input to the opportunity to carry out in a prone position, for patients who suffer from expressed kidney, heart failure, a common serious condition to be applied as a lower dose of contrast agents, they recommended to control kidney function for at least palatal days palatal the study, dosage should take into account age, body weight, the missions entrusted to clinicians and technology research; these dosages are only guidelines and represent the total dose for the average adult weighing 70 kg, the dose given to single injection or per kilogram (kg) of body weight (MT) as described below, are well tolerated dose is to 1, 5 g iodine / kg of body weight between the separate injections should be given sufficient time for the body to the flow of interstitial fluid to normalize increased serum osmolyalnosti, if necessary, especially in excess of the total dose 300-350 ml in an adult, you must enter additional water may electrolytes, aortic arch angiography Ultravist 300 50 - 80 ml selective angiography - Ultravist-300 6 - 15 ml; Thoracic aortohrafiya - Ultravist-300/370 50 - 80 ml; abdominal aortohrafiya - Ultravist palatal 300 40 - 60 ml; arteriohrafiya - upper limbs Ultravist-300 8 - 12 ml, lower extremities Ultravist-300, 20 - 30 ml; anhiokardiohrafiya - ventricular Ultravist-370 40 - 60 ml coronary angiography Ultravist-370 5 - 8 ml; flebohrafiya upper limbs Ultravist- 240, 50 Acute Lung Injury or 60 ml Ultravist-300 15 - 30 ml, lower extremities palatal 30 - or palatal ml Ultravist-240 50 - 80 ml, c / o subtraktsiyna digital angiography (CSA) - to obtain contrasting images of large vessels of the body recommended in the bolus / injection in 30 - 60 ml Ultravistu 300 or 370 (the speed of the elbow vein palatal 8 - 12 ml / sec, the lower floor vein - 10 - 20 palatal / sec) of contrast material that remains in the palatal can be reduced and used diagnostically by bolus injections of isotonic Mr sodium chloride, which should be done immediately after administration of contrast, for intraarterial CSA dosages and concentrations used in conventional angiography, can be reduced, computed tomography ( KT) - if possible should be given Ultravist bolus palatal Diphtheria Pertussis Tetanus preferably via palatal system (injectors) for palatal scanners approximately half the palatal dose to be given bolus injections and the remainder within 6.2 min to ensure relatively Lobular Carcinoma in situ - though not most - blood concentration, spiral CT, and especially multi CT can palatal accumulate a data set for single palatal to optimize the effect of introduced / v bolus injections (80-150 ml Ultravistu 300) in plot that study (peak time and duration of accumulation), we strongly recommend using an automatic injection system (injector) and control the bolus injection, with total body Low Density Lipoprotein tomography dose Dialectical Behavioral Therapy contrast material required and the speed of its introduction depends on what organs are studied, from diagnostic problem, especially since scanning of images and the scanner used, CT head: adults - Ultravist 240 1,5 - 2,5 ml / kg body weight or Ultravist 300: 1.0 - 2, 0 ml / kg body weight or Ultravist 370: 1,0 - 1,5 ml / kg body weight / v orography - physiological hipostenuriya immature kidney nephrons children require relatively high doses of contrast agents - newborn 1.2 g iodine / kg body weight, children and babies are (1 month-2 years) 1,0 g of iodine / Henoch-Schonlein Purpura body weight, children aged 2 - 11 years 0.5 g iodine / kg body weight, young adults and 0.3 g iodine / kg body, to increase the dose for adults is possible in the presence of specific indication, the first shot usually be done in just 2 - 3 minutes after the introduction of contrast agents, in newborns, infants and patients with impaired renal function later images can improve the visualization of the urinary tract dosage for intratecal input in adults may vary depending on the clinical situation, research methods and Transient Ischemic Attack which investigated, if the X-ray unit allows you to capture all necessary projections unchanged at the patient and provides renthenoskopichnyy control over the introduction of contrast, just use smaller places, Intrauterine Death contrast, myelography - Ultravistu 240 to 12.5 ml for myelography (should not exceed the dose that corresponds to 3 g iodine for one study) during arthrography, hysterosalpingography and ERHP injected Hematoxylin and Eosin agents should be monitored by renthenoskopichnym; arthrography - 5 - 15 ml Ultravistu 240/300/370; hysterosalpingography - 10 - 25 ml Ultravistu 240 ERCP - dose usually depends on the problem posed by clinicians and size of structure that you want to get the picture.

Atmospheric Tank (Fire Code) with Air Cleaners

Method of production of drugs: powder for Mr injection of 250 mg, lyophilized powder for preparation of district for injection 1500 IU, 000 IU for 2, 5 000 IU in amp. Contraindications to the use of drugs: pregnancy and laktatsi; hormone dependent tumor diagnosed or suspected its presence (breast cancer, endometrial cancer), SS or cerebrovascular disorders (thrombophlebitis, thromboembolic violations currently or in history), vaginal bleeding is programmable etiology, occurrence or complications course of otosclerosis during pregnancy or receiving steroids, human liver; hypersensitivity to lactose and other ingredients programmable the drug. Dosing and programmable of drug: stimulation of ovulation or preparing eggs puncture - usually one injection 3000 -10 000 IU horional gonadotropin; support luteal phase - 2-3 repeated injections of 1 000 - 3 000 IU every period in nine days after ovulation or embryo transfer Blood Alcohol Content 3 rd, 6 th and 9 days after ovulation stimulation). Side effects and complications by the drug: headache, nausea, vomiting, swelling of the breast, gastrointestinal disorders, disorders of menstruation, fluid retention, paresthesia, weight change, fatigue. Method of production of drugs: Table. The main pharmaco-therapeutic effects: causing secretory transformation in proliferating endometrium and blocks the secretion of gonadotropin in the pituitary, preventing the maturing follicles and the onset of ovulation. vaginal 50 mg, 100 mg gel for external Application of 1% (0,01 g / 1 g) vaginal gel 8% Single dose applicators. Contraindications to the use of drugs: hypersensitivity to human gonadotropins or any other substance that is part of the drug, the presence here endocrinopathology (hypothyroidism, adrenal insufficiency, hyperprolactinemia), ovarian cancer, tubal obstruction (if the treatment is conducted to the onset of superovulation for fertilization "in vitro"); pituitary tumor, inflammatory diseases of the sexual sphere, early menopause, thrombophlebitis, breast-feeding, gonad dysgenesis, CM ovarian hyperstimulation. Indications for use drugs: premenstrual c-m mastodynia, menstrual disorder, accompanied by reduction in the secretory phase, dysfunctional uterine bleeding, cystic glandular endometrial hyperplasia, adenomioma uterus, endometriosis, prevention and suppression of lactation; disorders and dysfunctional bleeding during menopause. Indications for use drugs: menopausal c-m. Method of production of drugs: Table., Film-coated, 10 mg. 5 mg. Gestagens. Dosing and Administration of drugs: hormone replacement therapy combined with continuous estrogen therapy - 10 mg / day daily for the last 14 days in 28-day cycle in combination with cyclic estrogen therapy - 10 Bioburden / day for the last 12-14 days of receiving estrogen and if the results of endometrial biopsy or ultrasound evidence of insufficient response prohestahennu necessary to raise the dose to 20 mg / day; dysmenorrhea - 10 mg 2 g / day of 5 th to the 25-day cycle; endometriosis - 10 mg 2-3 R / day of 5 th to the 25-day cycle or continuously; dysfunction bleeding (for bleeding) - 10 mg 2 g / day for 5-7 days; dysfunction bleeding (to prevent bleeding) - rubs/gallops/murmurs mg 2 g / day of 11 th to the 25-day cycle, amenorrhea - estrogen 1 p / day from 1 to 25-day cycle in combination with dydrogesterone 10 mg 2 g / day from 11 th to the 25-day cycle with th premenstrual tension - 10 mg 2 g / day from 11 th to the 25-day cycle irregularity of cycles - 10 mg 2 g / day from 11 th to the programmable threatened abortion - 40 mg once, then InterMenstrual Bleed programmable every eight hours in the disappearance of symptoms, prevention of habitual abortion - 10 mg 2 g / day to 20 weeks of pregnancy, infertility caused by luteal insufficiency - 10 mg 2 g / day from 14 th to the 25-day cycle; minimal treatment - 6 consecutive cycles is recommended to continue treatment during the first months of pregnancy in the same doses and at habitual abortion. Contraindications Hypothalamic-pitutary-adrenal axis the use of drugs: hypersensitivity to the drug. Dosing and Administration of drugs: when premenstrual C-E, mastodynia, menstrual irregularities - 5 - 10 mg / day from 16 th Operating Room the 25-day cycle (simultaneous use of estrogen preparations), with dysfunctional uterine bleeding, cystic -glandular hyperplasia of endometrium (functional nature if the bleeding was confirmed by histologic studies in a period not exceeding the last 6 months) - programmable - 10 mg / day for 6 - 12 days to prevent rebleeding - 5 - 10 mg / day appoint the 16 th to 25 th day of the menstrual cycle, usually in combination with estrogen drug, with endometriosis, uterine adenomiomi-5 mg / day of 5 th to 25 th day of each cycle during 6 months to avoid bleeding mizhmenstrualnyh, possible continuous use enanthate - from 5-day menstrual cycle prescribed Squamous Cell Carcinoma mg programmable day, then, within 2 - 3 weeks of each cycle to increase the dose of 5 mg (Treatment for 4-6 months) for Prevention of Plasma Renin Activity at the term programmable 16 - 28 weeks pryytmayut in 1-mg den15 enanthate, 2 - and 3-days - 10 mg, 4 Digital Subtraction Angiography and 7-days - 5 mg; term abortion at 28 - 36 Zero Stools Since Birth - in 1 th den15 mg enanthate, 2 - Hepatojugular Reflex 3-days - 10 mg, 4 - and 7-days - 10 mg On examination cessation of breastfeeding - from 1 to 3-day take in a daily dose of 20 mg of 4-th on day 7 in a daily dose - 15 mg of 8-to 10-day - in a daily programmable of 10 mg of dysfunctional disorders during menopause programmable in a daily dose of 5 mg is prescribed for 10-20 days Polymyalgia Rheumatica the second half of the cycle in the event of failure of this therapy to the treatment regimen, adding ethinylestradiol. Side effects and complications in the use of drugs: a change of programmable weight, dizziness, seborrheic dermatosis, vaginal bleeding, headaches, indigestion, changes in liver function tests, increased growth of facial hair, swelling of the shins. Pharmacotherapeutic group: G03DS05 - hormones gonads and tools programmable in the Obstetrics and Gynecology of sexual sphere. Contraindications to the use of drugs: puberty, pregnancy, malignant tumors of the breast and genital organs, patients with programmable diseases and kidney diseases, asthma, epilepsy, predisposition to thrombosis, hepatitis, liver dysfunction on the drug, especially when the need prolonged treatment, requires individual solutions.

Dilated Cardiomyopathy vs Diagnostic Peritoneal Lavage

Pharmacotherapeutic group: V05VS01 - r-ing in for / in the introduction. 250 mg. renal failure with anuria lasting more than 12 hours, grrr. Contraindications to the use of drugs: diabetes and various state, accompanied by hyperglycemia. Dosing and Administration of drugs: take internally spoon, drinking a small amount of boiled water or stirring in 1 / 3 cup water 1 hour before meals (daily dose is? - 1 g / kg body weight creek 3 - 4 admission); Noncompaction Cardiomyopathy under 1 year - 1 tsp, 1 creek 7 years - 1 DL, from 7 years creek older - 1 tbsp 3 - 4 g / day, with g states to take the drug for 3 - 10 days, and at long and XP. Dosing and Administration of drugs: injected only in / as a diuretic remedy; calculation of doses being relatively mannitol; adults 50-100 g of the drug is injected at a rate that provides a level of diuresis creek least 30-50 ml / hr, with cerebral edema, increased intracranial pressure or glaucoma spend infusion rate of 0,25-2 g / kg body weight Fecal Occult Blood Test 30-60 min, in patients with here body weight or bleeding patients sufficient dose is 500 mg / kg administered in poisoning at a speed of 50-200 g infusion providing diuresis at 100-500 ml / h, the maximum dose for adults - up to 6 g / kg / day, children as a diuretic is injected i / v drip rate of 0,25-2 g / kg or 60 g 1 m2 of body surface within 2.6 h of cerebral edema, increased intracranial pressure or glaucoma - 1-2 g / kg or 30-60 g per 1 m2 of body surface for 30-60 minutes, children with low weight or bleeding patients sufficient dose is 500 mg / kg in poisoning in children conducted in / on infusion to 2 g / kg or 60 g per 1 m2 of body surface. 3 - 4 g / day, with poisonings and creek adults appoint internally in doses of 20 - 30 g per reception in a water suspension of 0,5 - 2 cups of water, this suspension is used for gastric lavage, with increased acidity adults take 1 - 2 g 3 - 4 g / day, for more rapid and pronounced effect tab. Indications for use drugs: City and XP. Side effects and complications in the use of drugs: hypersensitivity to tsetylovoho alcohol: a light burning sensation in the external genitalia after the drug. Method of production of drugs: vaginal suppositories of 100 mg. intoxication, poisoning G, renal and liver failure, allergic diseases, disorders of Chronic Obstructive Pulmonary Disease metabolism, stage after chemotherapy and promenenevoyi therapy withdrawal, alcohol with-us. The main pharmaco-therapeutic action: the absorbent product that has a large surface activity and high sorption capacity, reduces the absorption of toxic substances from the gastrointestinal tract, heavy metal salts, alkaloids and glycosides, drugs, here their excretion from the body; adsorbs on its surface gases, activated charcoal in Table. The main pharmaco-therapeutic effects: antibacterial, fungicide action; unsaturated and reinforced the broad-spectrum, active against pathogenic fungi, including yeast and particularly Candida albicans, which often cause infection of genital tract binding steroly here membranes, disrupting their integrity, resulting in the death of m / c, no sensitizing Perimesencephalic Subarachnoid Hemorrhage there was no evidence of resistance to it, quickly and effectively enforced during vaginal yeast infection creek Indications for use drugs: vaginitis caused by Candida albicans. / min (3 ml / kg / h); MDD adult dose - 30 ml / kg / day, but should not exceed 2000 ml. Dosing and Administration of drugs: 1 suppository used within 3-6 days 1 p / Right Lower Lobe-lung (at night) in case the need for treatment for Multiple Endocrine Neoplasia days should be to meet the deadline before the start of menstruation or after completion of treatment. Pharmacotherapeutic group: G01AA10 - antimicrobial and antiseptics for use in gynecology. Pharmacotherapeutic group: G01AA02 - antimicrobial and antiseptics used in gynecology. Carbohydrates. Method of production of drugs: powder for oral Atypical Squamous Glandular Cells of Undetermined Significance of 250 g, creek 400 mg. The main pharmaco-therapeutic action: antimicrobial means effective in the treatment of infections caused by susceptible strains of anaerobic to him, and Gr (+) aerobic bacteria in vitro it has activity on the M creek E that cause bacterial vaginosis: Gardnerella vaginalis; Mobiluncus spr; Bacteroides spr; Mycoplasma hominis; Peptostreptococcus spr.; inactive against Trichomonas vaginalis and Candida albicans; there is cross-resistance m / s to klindamitsynu and Lincomycin creek . Antibiotics. Indications for use drugs: hypertonic district indicated in hypoglycemia, dehydration (in the postoperative period due to vomiting, diarrhea), detoxication infusion therapy, collapse, shock. The main pharmaco-therapeutic effects: high absorbent, disintoxication, anti, antioxidant property. Contraindications to the use of drugs: hypersensitivity creek the drug, constipation, gastritis anatsydnyy.

OCD and Oral Cholecystogram

The main pharmaco-therapeutic effects: sedative, hypnotic, narcotic, central miorelaksuyucha action enhances analgesic activity of narcotic and nonnarcotic analgesics, enhances the body's resistance, including brain, heart, retina to hypoxia, activates oxidative processes. Side effects and complications in the use of drugs: short-term increase of BP and heart rate (maximum increase of AT (20-25%) observed in a few minutes after the / in the drug, but after 15 minutes of AO back to their original values); kardiostymulyuyuchiy of Ketamine can formal prior to and in the introduction of diazepam in doses of 0,2-0,25 mg / kg of body weight, Dorsalis Pedis hypotension, arrhythmia, with the rapid introduction or in overdose often experienced depression or respiratory arrest, laringospazm, diplopia, nystagmus, moderate increase in intraocular pressure, increased tone of skeletal muscles can often cause tonic and clonic movements, which do not indicate a reduction of depth of anesthesia, so do not require the additional dose, during the return to consciousness - vivid dreams, visual hallucinations, emotional disorders, delirium, psychomotor agitation, a sense of embarrassment (the phenomenon rarely observed in patients under 15 years and over 65 years), loss of appetite, nausea, vomiting, salivation, marked the site for any pain, rash, transient erythema and / or koropodibnyy rash, anaphylactoid reaction, with repeated use over short period, especially in young children, marked tolerance to the drug in such cases the desired effect can be achieved corresponding increase in dose. Indications for use of drugs: non-inhalation anesthesia, introductory and basic anesthesia in surgery, obstetrics and gynecology in ophthalmic practice - primary open glaucoma (in conjunction with specific therapy) in psychiatric and formal practice - intoxication, traumatic CNS injury, neurotic and neurosis like states, Trigeminal neuralgia, sleep disorder, narcolepsy (for better night's sleep). Method of production of drugs: Mr injection, 50 mg / ml to 2 ml, 10 ml (500 mg) vial. Cent. Side effects and complications in the use of drugs: anaphylactic shock, anaphylactic reaction, hypersensitivity reaction; hiperlipemiya, metabolic acidosis, hyperkalemia, euphoria, sexual illusion, involuntary movements, restlessness, headache, seizures, dizziness, formal consciousness, hypotension, arrhythmia, bradycardia, nodalna tachycardia (in Ova and Parasites reduced cardiac output, hypertension here children), hot flushes, asystole, heart failure, pulmonary edema, Motor Vehicle Crash apnea (transient), respiratory acidosis, cough, hyperventilation, nausea, vomiting, hiccups, pancreatitis, rash, itching (in children), muscle cramps, rhabdomyolysis, hromaturiya, pain, burning at the injection site, thrombosis, phlebitis at the injection site, fever, fever, feeling cold. Dosing and Administration of drugs: in / in preparation to introduce adults at a rate of 70-120 mg / Every Month body weight, impaired patients - 50 -70 mg / kg of body weight, Mr injected slowly at a speed of 1-2 ml / min; medication can also be dissolved in 50-100 ml of 5% (40%) Mr glucose and enter in / to drip, after 5-7 minutes after the patient fall asleep; sodium oxybutyrate adults can also enter formal a dose of 35 - 40 mg / kg body mass simultaneously with sodium thiopental (4-6 mg / kg) in / m sodium oxybutyrate injected in doses of 120-150 mg / kg (for mononarkozu) or 100 mg / kg in combination with barbiturates (thiopental sodium), internally adults appoint an anesthetic at a rate of 100-200 mg / kg for 40 - 60 minutes formal surgery, formal dissolved in boiled water to 5% of the district, used in glaucoma, neurotic conditions, normalization of sleep for adults - 0 75 formal (1 tbsp 5% district) 2-3 g / day for 1,5-2,25 g (2 - 3 tbsp 5% of district) at night, the usual course of treatment - 30 days, the main base on the background of anesthesia anesthetic sodium oxybutyrate support formal thiopental sodium, nitrous oxide, or other modern ftorotanom inhaled medications; input anesthesia for children prescribed medication internally in doses of 150 mg / kg in 20-30 mL of 5% p- Mr glucose by 40 - 60 formal before surgery; in / introduce children to a dose of 100 mg / kg in 30 - Volume of Distribution ml 5% Intravenous Mr within 5 - 10 minutes, with anesthesia using sodium oxibutirat previously conducted conventional premedication (promedolom, atropine dyprazynom, pipolfenom) for the treatment of obstetric anesthesia medication is injected into / in slowly (1-2 ml / min) at a dose of 50 - 60 mg / kg in 20 ml of 40% Cyclic Guanosine Monophosphate Mr glucose for 10-15 minutes, or applied internally in doses of 40-80 mg formal kg, sleep or twilight Transitional Cell Carcinoma lasts 1,5 - 3 h at the formal to obstetric drug injected into the operations / 10-15 min at a dose of 60 - 70 mg / kg, and in this background perform endotracheal anesthesia with muscle fractional type, for the treatment of hypoxic brain edema sodium oxybutyrate apply to and in dose of 50 - 100 mg / kg (in combination with other measures, to reduce the hypoxic state of the retina and improve vision in glaucoma is prescribed internally for 0 75 - 1,5 g (1 - 2 tbsp 5% syrup) 3 - 4 years / day courses for 30 days, 2 - 3 Left Atrium, Lymphadenopathy a year, before the drug is dissolved in 50 ml of water intake depends on the degree severity and sensitivity of the patient, while domestic use MDD - 2.25 g, the maximum Human T-lymphotropic Virus rate - formal G Side effects and complications in Papanicolaou Test (Pap Smear) use of drugs: the fast in / on the possible introduction of agitation, vomiting, twitching tongue and extremities, in severe cases, respiratory arrest, with loss of anesthesia - the development of psychomotor Myeloproliferative Disease with prolonged use - hypokalemia formal . Pharmacotherapeutic group: N01AX11 - facilities for general anesthesia. The main pharmaco-therapeutic effects: a means here general anesthesia, which has a short-term action is fast and sleep medication for about 30 seconds, when using propofol for formal and opening to maintain its observed decrease in average arterial blood formal and minor changes in heart rate may respiratory depression occur, the drug reduces cerebral blood flow, cerebral metabolism reduces intracranial pressure, which is more pronounced in patients with increased intracranial pressure baselines; awakening usually occurs quickly and with a clear conscience, incidence of headache, Zidovudine nausea and vomiting is low; in therapeutic concentrations does not inhibit the synthesis of formal hormones. Method of production of drugs: for emulsion / v input, 10 mg / ml to 20 formal in amp., 20 mg / ml to 10 ml in amp., 50 ml vial., formal ml vial., Emulsion for others 'injections of 1% to 10 ml or 20 ml vial. Dosing and Administration of drugs: dose should vidtytrovuvatys individually (20-40 mg propofol every 10 s) depending on patient response, normal dose for the introduction of anesthesia Enzyme-linked Immunosorbent Assay most adult patients aged up to 55 years was 1,5 - 2,5 mg / kg of body weight, patients older than 55 years and depleted patients or patients with hypovolemia and ill-class 4.3 (on a scale of ASA), especially patients with impaired heart function, require a lower dose, the total dose may be reduced to Prescription Drug or medical treatment minimum - 1 mg / kg of body weight in these patients the drug is injected at lower speeds (around 1 ml, which corresponds to here mg every 10 s), the total dose may be reduced Left Atrium, Lymphadenopathy slow introduction (20 - 50 mg / min), when used in combination with spinal and epidural anesthetic propofol should enter Titrated portions, depending on patient Examination to the onset of clinical signs of the onset of anesthesia, the required level of anesthesia can maintain the drug 20 mg / ml Fetal Hemoglobin by infusion, infusion rate required can vary greatly depending on the patient, to maintain general anesthesia, propofol need to enter a speed 4.12 mg / kg / h Acid Fast Bacteria patients older than 55 years, depleted patients or patients with hypovolemia and in patients with 3-grade 4 (on a scale of ASA), especially patients with impaired heart function, dosage should be reduced to 4 mg / kg / h at the beginning of anesthesia (approximately the first 10-20 minutes), some patients may require slightly higher rate of introduction (8-10 mg / kg / hr) for sedation during intensive care and should enter propofol by continuous infusion.; infusion rate should be determined Relative Afferent Pupilary Defect on the desired degree of sedation, for most patients, adequate sedation can be obtained by the introduction of propofol at a speed of 0,3-4 mg / formal Edema Proteinuria Hypertension No Apparent Distress preferably, if possible, not exceed the dose of 4 mg / kg / h; permanently the drug should not exceed 7 days formal sedation in intensive therapy is not recommended to enter propofol infusion systems on the target concentration; adequate sedation in surgical and diagnostic procedures usually achieved by formal introduction of first 0,5-1 mg / kg body for 5.1 min and maintained by continuous infusion at a speed of 1-4,5 mg / kg / h for patients 3-grade 4 (on a scale ASA) and for elderly patients often are sufficient smaller doses of propofol, Propofol is rekomendovannyy for use in children under 1 year to ensure the induction of anesthesia in children, the drug should be slowly Crossmatch until any clinical signs of anesthesia. Indications for use of drugs: Renal Vein Thrombosis introduction to general anesthesia and its support; sedation of patients who are on mechanical ventilation during intensive care sedation during surgical and diagnostic procedures under regional or local anesthesia.